Research News on Targeted Therapies
-
Experimental Iniparib May Help Treat Triple-Negative Disease
A small, early study suggests that the experimental PARP inhibitor iniparib can help treat metastatic triple-negative breast cancer.
-
Women Treated with Avastin Have Higher Risk of Congestive Heart Failure
Women treated with Avastin for advanced-stage breast cancer were four to five times more likely to develop congestive heart failure compared to women who didn't get Avastin. Still, the overall risk of heart failure was low.
-
FDA Recommends Removing Avastin’s Breast Cancer Indication
The FDA has recommended removing the breast cancer indication from Avastin because the medicine has not been shown to be safe and effective for that use.
-
Experimental Combo of Herceptin and Omnitarg Helps Treat Advanced-Stage HER2-Postitive Disease
Treatment before surgery with Herceptin and Omnitarg alone or with Taxotere benefited women diagnosed with locally-advanced or inflammatory HER2-positive breast cancer.
-
Experimental Iniparib Shows Promise in Treating Advanced-Stage Disease
A small, early study suggests that some advanced-stage cancers may respond to an experimental combination of iniparib and Camptosar.
-
Real World Survival Stats for Avastin Mirror Clinical Results
Analysis shows that the real world survival statistics of women diagnosed with metastatic breast cancer and treated with chemotherapy and Avastin were similar to survival statistics of women in clinical trials looking at the same combination.
-
Researchers Recommend Having Port in Place for Week Before Starting Avastin
Research shows that doctors should wait at least 1 week after a venous access line is put in before giving Avastin.
-
Avastin Added to Chemo Before Surgery Offers No Benefit
Research shows that adding Avastin to neoadjuvant chemotherapy doesn't seem to benefit women diagnosed with early-stage or locally-advanced breast cancer.
-
Herceptin and Tykerb Added to Chemo Before Surgery More Effective Than Adding Only One to Treat Early-Stage, HER2-Positive Disease
Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows.
-
Herceptin More Effective Than Tykerb When Given Before Surgery
Research suggests that Herceptin is more effective than Tykerb in a neoadjuvant regimen for early-stage or locally-advanced HER2-positive breast cancer.
